NEW YORK (GenomeWeb) – Synthetic biology firm Gen9 has raised $25 million in a private financing round, its president and CEO confirmed to GenomeWeb Daily News.

The company disclosed the financing in a document filed with the US Securities and Exchange Commission last week. Gen9 President and CEO Kevin Munelly told GWDN in an email today that proceeds from the financing will be used to "expand our team and advance additional products and services that will further accelerate the design-build-test cycle for our customers."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.